Stocks · News reference
Amneal Pharmaceuticals is expanding its production capacity for estradiol patches to address significant demand following the removal of an FDA warning.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Matthew Cascio, formerly Senior Director of Corporate Development and Head of Specialty Business Development at Amneal Pharmaceuticals, has been appointed as Vice President and Head of Business Development at Laxxon Medical.
Amneal Pharmaceuticals received a price target increase to $24.00 per share, while maintaining an Overweight rating from analysts.
Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.